CSIMarket Company Name, Ticker, Customers, else..
 
Grace Therapeutics Inc  (NASDAQ: GRCE)
 
Price: $2.1400 $-0.09 -4.036%
Day's High: $2.240000009536743 Week Perf: -5.31 %
Day's Low: $ 2.14 30 Day Perf: -0.93 %
Volume (M): 65,461 52 Wk High: $ 5.18
Volume (M$): $ 0 52 Wk Avg: $3.05
Open: $2.24 52 Wk Low: $1.79



 Market Capitalization (Millions $) 37
 Shares Outstanding (Millions) 17
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


The company develops and commercializes drug delivery technologies targeting rare and orphan diseases by reformulating existing pharmaceutical compounds. Its pipeline includes three clinical-stage drug candidates aimed at improving efficacy and reducing side effects for conditions such as aneurysmal subarachnoid hemorrhage, ataxia-telangiectasia, and postherpetic neuralgia. The company employs proprietary formulations and utilizes the FDA's Section 505(b)(2) regulatory pathway, seeking to expedite approval processes and obtain orphan drug designations.


   Company Address: 103 Carnegie Center Suite 300 Princeton 8540 NJ
   Company Phone Number: 322-1602   Stock Exchange / Ticker: NASDAQ GRCE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMRN   -3.82%    
BMRN        0.5% 
INSM   -4.83%    
RARE   -9.99%    
SRPT   -10.26%    
VRTX   -1.51%    
• View Complete Report
   



Financing Agreement

Grace Therapeutics Secures Up to $30 Million in Strategic Private Placement Financing, Fueling Growth in Innovative Healthcare Solutions,

Published Mon, Feb 10 2025 1:05 PM UTC

Grace Therapeutics Secures Up to $30 Million in Private Placement Financing: Implications for Future Growth in the Healthcare SectorIn a significant development for the biotech landscape, Grace Therapeutics has announced a private placement financing initiative aimed at raising up to $30 million. This strategic move is spearheaded by Nantahala Capital and ADAR1 Partners, LP,...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.77
PEG (TTM) -

Financial Strength Current
Quick Ratio 8.24
Working Capital Ratio 8.59
Leverage Ratio (MRQ) 0.04
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.18 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.8 $
Book Value 2.79 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.